Christine E. Swenson

Author

Also Known As

C E Swenson, C Swenson, C. E SWENSON, C. E. SWENSON, C. E. Swenson, C.E. Swenson, CHRISTINE E. SWENSON, Christine E. Swenson, Christine Swenson, Swenson, C.E.

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

Cornell University University of California, San Francisco Population Council The University of Texas Health Science Center at Houston Presbyterian Hospital

About

Christine E. Swenson is an author at Cornell University specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	17	982
2	Health Sciences	3	3	107
3	Public Health	2	2	83
4	Natural Sciences	1	1	121
5	Allergy	1	1	74

Christine E. Swenson

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia Eric J. Feldman, Jeffrey E. Lancet, Jonathan E. Kolitz, Journal of Clinical Oncology	2011	299
Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors Gerald Batist, Karen A. Gelmon, Kim N., Clinical Cancer Research	2009	210
Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study K. Mross, Bernward Niemann, Ulrich Massing, Cancer Chemotherapy and Pharmacology Solid TumorsMedicinePharmacologyLiposomal DoxorubicinPharmacotherapy	2004	135
Liposome technology and the development of Myocet™ (liposomal doxorubicin citrate) Christine E. Swenson, Walter R. Perkins, Patricia J. Roberts, The Breast Lipid PreparationLiposome TechnologyLipid ChemistryCell BiologyBiomolecular Engineering	2001	130
Liposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige mice S P Klemens, Michael H. Cynamon, Christine E. Swenson, Antimicrobial Agents and Chemotherapy	1990	121
Amphotericin B Lipid Complex (Ablc™): A Molecular Rationale for the Attenuation of Amphotericin B Related Toxicities A S Janoff, Walter R. Perkins, Stephen Saletan, Journal of Liposome Research Liposome MembranesMolecular PharmacologyMedicinal ChemistryDrug-lipid InteractionsBioorganic Chemistry	1993	121
Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer Christine E. Swenson, Lois E. Bolcsak, Gerald Batist, Anti-Cancer Drugs	2003	112
Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia Eric J. Feldman, Jonathan E. Kolitz, J M Trang, Leukemia Research Pharmaceutical ScienceAdvanced LeukemiaMedicineMolar Ratio FormulationPharmacotherapy	2012	98
Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies Adedayo Adedoyin, J F Bernardo, Christine E. Swenson, Antimicrobial Agents and Chemotherapy Nonlinear PharmacokineticsPharmaceutical ScienceAntifungal AgentPharmacological StudyPharmacokinetic Profile	1997	90
Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity Walter R. Perkins, Sharma R. Minchey, Lawrence T. Boni, Biochimica et Biophysica Acta (BBA) - Biomembranes MedicineApoptosisCell DeathCellular PharmacologyCellular Biochemistry	1992	87

Page 1